Core Viewpoint - Ascentage Pharma Group International is actively participating in investor conferences in December 2025, highlighting its ongoing commitment to engage with the investment community and showcase its advancements in biopharmaceuticals [1][7]. Company Overview - Ascentage Pharma is a global, commercial stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for unmet medical needs in cancer [2]. - The company has developed a robust pipeline of innovative drug products, including inhibitors targeting key apoptotic pathway proteins and next-generation kinase inhibitors [2]. Product Portfolio - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for treating chronic myeloid leukemia (CML) with specific mutations, and is included in the China National Reimbursement Drug List [3]. - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for various hematologic malignancies, currently being commercialized in China after receiving NMPA approval for chronic lymphocytic leukemia/small lymphocytic lymphoma [4]. - Ascentage Pharma is conducting multiple global registrational Phase III trials for both Olverembatinib and Lisaftoclax, indicating a strong focus on expanding its clinical footprint [3][4]. Research and Development - The company has established a portfolio of global intellectual property rights and formed partnerships with leading biotechnology and pharmaceutical companies, enhancing its research capabilities [5]. - Collaborations include relationships with prominent research institutions, which support the company's innovative drug development efforts [5].
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025